Meropenem Tamrisa (Meropenem)

Meropenem is a broad‑spectrum carbapenem antibiotic used to treat infections caused by susceptible bacteria in various organ systems.

• Complicated intra‑abdominal infections: provides bactericidal activity against mixed aerobic and anaerobic pathogens, facilitating resolution of the infection.
• Complicated urinary tract infections: eliminates resistant Gram‑negative organisms, helping achieve clinical cure and microbiological eradication.
• Hospital‑acquired pneumonia including ventilator‑associated pneumonia: penetrates lung tissue to eradicate causative bacteria and improve respiratory outcomes.
• Bacterial meningitis: achieves therapeutic concentrations in cerebrospinal fluid to treat severe central nervous system infections.

• Meropenem binds with high affinity to penicillin‑binding proteins (PBPs) located on the bacterial cell wall, inhibiting the final transpeptidation step of peptidoglycan synthesis. This blockade weakens the cell wall, leading to osmotic instability and bacterial lysis. The molecule is resistant to most β‑lactamases, allowing activity against a wide range of Gram‑negative and Gram‑positive organisms, including many multidrug‑resistant strains.

Adverse reactions to meropenem may vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: may be watery and self‑limiting.
• Rash: erythematous skin eruption.
• Elevated liver enzymes: transient increase in transaminases.

Serious or Rare Side Effects

• Seizures: especially in patients with renal impairment or CNS disorders.
• Anaphylaxis: severe hypersensitivity reaction requiring immediate medical attention.
• Clostridioides difficile‑associated colitis: may cause severe diarrhea and colitis.
• Stevens‑Johnson syndrome/toxic epidermal necrolysis: rare but life‑threatening skin reactions.

When using meropenem, clinicians should consider several safety precautions.

• Renal function: adjust dose in patients with impaired kidney function to avoid accumulation.
• Seizure risk: monitor closely in patients with a history of seizures or central nervous system disorders.
• Hypersensitivity: avoid in individuals with known allergy to carbapenems or other β‑lactam antibiotics.
• C. difficile infection: be vigilant for signs of colitis during and after therapy.
• Concomitant nephrotoxic drugs: use with caution when combined with other agents that may affect kidney function.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid)

• Valproic acid: concomitant use can markedly reduce valproate plasma concentrations, increasing seizure risk.
• Other carbapenems: concurrent administration may increase toxicity without added benefit.
• Aminoglycosides: combined use can enhance nephrotoxicity.

Moderate Interactions (Monitor Closely)

• Loop diuretics: may potentiate renal effects; monitor kidney function.
• Oral contraceptives: meropenem may reduce hormonal efficacy; advise alternative contraception.
• Anticoagulants (warfarin): may alter INR; check coagulation parameters regularly.
• NSAIDs: increased risk of renal impairment; assess renal function.